Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-1430-2026

Hitachi, Ltd. Radiation Oncology Systems, Kashiwanoha recalls Brand Name: Hitachi Proton Beam Therapy REF: PROBEAT-CR

Hitachi, Ltd. Radiation Oncology Systems, KashiwanohaKashiwa, JapanReported Mar 4, 2026 · 4 months ago
Legal News Analyst ·

Reason for recall

Software anomaly in the patient positioning system may result in positional discrepancy.

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

Affected products & lots

  • Brand Name: Hitachi Proton Beam Therapy REF:PROBEAT-CR
    Affected lot
    CRUS01/

What the firm is doing

Between the dates of February 5-11, 2026, Hitachi, Ltd, issued an "URGENT: MEDICAL DEVICE RECALL" notification dated January 21, 2026, via Service Team Manager to affected consignees. Hitachi is asking consignees to take the following actions: 1. Until the PPS software has been updated with the corrected version, users are instructed to follow the System Operation instruction in the document. 2. Users are also asked to post the document in a prominent space and sign its cover. 3. Complete and return the acknowledgment and receipt form. Action by the firm: Hitachi plans to update the PPS software to a corrected version that prevents the mismatch between the commanded error correction parameter and the internal variable. starting in late March 2026 and the users will be contacted after the update. If you have any questions, please call QA Manager at Tel: (408) 986-6300. Monday through Friday, 8:00 AM to 5:00 PM, Central Time.

DistributionShow details

US distribution to states of: TX, Washington DC

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls